Summary
In our recent study, a new sustained release dosage form of nitrofurantoin (nft) as matrix tablets by 22 factorial design has been prapared by using different drug: polymer ratios. The effect of the polyvinylpyrolidone contents of nft matrix tablets on dissolution rate and bioavailability of the drug have been evaluated. The ideal formulation which fitted at USP XXII dissolution norms was tested by in vivo experiments. The satisfactory correlation was also obtained between the in vivo and the in vitro results.
This study suggested that the amounts of nft excreted in urine can be calculated by using in vitro dissolution results and sampling time.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
BanakarUmesh V. (1992): Pharmaceutical Dissolution Testing. New York, Marcel Dekker, pp. 359–373.
Levy G., Hollister L.E. (1964): Inter and intrasubject variations in drug absorption kinetics. J. Pharm. Sci., 53, 1446–1452.
Wagner J.G., Nelson E. (1964): Kinetic analysis of blood levels and urinary excretion in the absorption phase after single doses of drug. J. Pharm. Sci., 53, 1392–1403.
Loo J.C.K., Riegelman S. (1968): New method for calculating the intrinsic absorption rate of drugs. J. Pharm. Sci., 57, 918–928.
Yuen K.H., Desmukh A.A., Newton J.M. (1993): In vivo/in vitro correlation of experimental sustained release theophylline formulations. Pharm. Res., 10, 588–592.
Hussein Z., Friedman M. (1990): Release and absorption characteristics of novel theophylline sustained release formulations: in vitro-in vivo correlations. Pharm. Res., 7, 1167–1171.
Karasulu H.Y., Ertan G., Güneri T. (1993): Pharmacokinetics and bioavailability of nitrofurantoin matrix tablets. Eur. J. Drug Metab. Pharmacokinet., 18, 108–114.
Mortada S.A.M., El-Egaky A.M., Motawi A.M., Khodery K.A. (1987): Preparation of microcapsules from complex coacervation of gantrez-gelatin. II In-vitro dissolution of nitrofurantoin microcapsules. J. Microencapsulation, 41, 23–37.
Concheiro M., Labres M.L., Vilo-Jato R., Martinez R., Blanco J. (1987): Dissolution rate and bioavailability of sipirinolactone tablets: effect of various technological factors. Drug Dev. Ind. Pharm., 13, 2301–2314.
Vilo-Jato J.L., Concheiro A., Seijo B. (1987): Effect of aging on the bioavailability of nitrofurantoin tablets containing carbopol 934. Drug Dev. Ind. Pharm., 13, 1315–1327.
Martindale (1989) Nitrofurantoin. In: Extra Pharmacopoeia, 29th edn. London, Pharmaceutical Press, pp. 272–274.
Kunin C.M. (1967): A guide to use of antibiotics in patients with renal disease. Ann. Intern. Med., 67, 151–158.
Baichwal M.R., Shetty U.C. (1982): Studies on retardation of release of nitrofurantoin. Ind. J. Pharm. Sci., 44, 48–51.
Cadwallader D.E., Jun H.W. (1976): Nitrofurantoin Anal. Profiles Drug Substances, 5, 345–374.
Eldem T., Capan Y. (1983): Formulation studies on sustained release nitrofurantoin tablets. Proc. 3rd Int. Conf. Pharm. Tech., APGI. Paris, 1, 137–144.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Karasulu, H.Y., Ertan, G., Köse, T. et al. In vivo/in vitro correlations of nitrofurantoin matrix tablet formulations. European Journal of Drug Metabolism and Pharmacokinetics 21, 27–31 (1996). https://doi.org/10.1007/BF03190275
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190275